Beta-Blocker Use Across Indian Cardiovascular Practice: Top Takeaways from ROBUST Study - Video

The ROBUST study, one of India's largest cardiovascular KAP (Knowledge, Attitude, and Practice) studies, provides valuable real-world insights into beta-blocker use across the cardiology care continuum.

Conducted among 1,000 healthcare professionals, including consulting physicians, cardiologists, and other specialists, the study assessed prescribing patterns in hypertension, heart failure, post-myocardial infarction (post-MI), chronic coronary syndrome, and atrial fibrillation. The findings were published in the February 2026 issue of JAPI.

A key highlight is the consistent preference for metoprolol, which emerged as the most widely used beta-blocker across all major indications. Beta-blockers were commonly prescribed in hypertensive patients, especially those with elevated heart rate and higher cardiovascular risk. In heart failure and post-MI care, they were recognized as essential therapies, with significant use at discharge to improve outcomes.

Metoprolol also demonstrated meaningful blood pressure reductions in routine practice, reinforcing its clinical effectiveness. Overall, the ROBUST study offers important India-specific evidence, helping bridge the gap between clinical guidelines and real-world practice while supporting optimized cardiovascular care.